Document:

Unassociated Document

    Exhibit
      10.5

     

    

      CONSULTING
        AGREEMENT

      

      This
        Consulting Agreement (this “Agreement”)
        is
        made on August 29th,
        2006,
        by and between WinWin Gaming, Inc., a Delaware corporation (“Client”),
        and
        Calico Capital Management, LLC, a Delaware limited liability company
        (“Consultant”).

       

      1.  Engagement
        of Consultant.
        Client
        hereby engages Consultant to render consulting services to Client on a
        non-exclusive basis and on the terms and for the consideration specified
        herein.
        As such, Consultant will familiarize itself to the extent it deems necessary
        and
        appropriate with the business, operations, condition (financial and otherwise)
        and prospects of the Client and will provide advice on the capital structure
        of
        the Client, financing options, types of financial instruments to be offered,
        and
        the likely market segment which the financial instruments are suitable. The
        Consultant may identify possible investors interested in providing capital
        to
        the Client or otherwise participating in a Transaction (as defined below)
        pursuant to terms to be negotiated by and among such possible investors and
        the
        Client (without the involvement of the Consultant), and, at the option of
        Consultant, will provide consulting services with respect to any Transaction.
        If
        the Consultant, after becoming familiar with potential transactions of the
        Client, declines to render advice to the Client with respect to a particular
        Transaction, Consultant shall not enter into any other engagement with a
        third
        party with respect to such Transaction. Client understands that no particular
        result is promised or can be guaranteed by Consultant in rendering the services
        for any particular matter or with respect to any Transaction. Consultant
        undertakes to render the services competently and with professional skill.
        Client will provide Consultant with such factual information and materials
        as
        Consultant may require to perform such consulting services. Client shall
        determine the scope of the work to be performed, but after having agreed
        to
        perform such services, Consultant shall determine the means, manner and method
        of performing these services. For purposes of this Agreement, a “Capital
        Transaction”
shall
        mean any private placement of any securities of Client (including debt, equity
        or any derivative or convertible securities) with investors identified by
        Consultant and any other investors who participate in such transaction through
        the direct or indirect efforts of Consultant (“Consultant
        Identified Investors”).
        For
        purposes of this Agreement, an “M&A
        Transaction”
shall
        mean (i) any acquisition of outstanding capital stock or control of the
        outstanding capital stock or all or substantially all of the assets of companies
        made by the Client by one or more Consultant Identified Investors or (ii)
        any
        merger, consolidation, tender or exchange offer, leveraged buyout, acquisition
        or sale of substantially all of Client’s assets or equity interests,
        recapitalization involving the distribution of cash, securities or property
        to
        Client’s equity holders or similar transactions involving all or a substantial
        part of the business, assets or equity interests of Client and/or its affiliates
        in one or more transactions. A “Transaction”
shall
        mean any Capital Transaction or a M&A Transaction and any additional matters
        identified in advance and mutually agreed to in writing by Consultant and
        Client. 

       

      Consultant
        is not a registered “broker” or “dealer” as such terms are defined in Section
        3(a)(4) and 3(a)(5) of the Securities Exchange Act of 1934, as amended (the
        “Exchange Act”) and will not act to effect any transactions in securities for
        the account of Client. With
        respect thereto and notwithstanding anything set forth herein to the contrary,
        in connection with any Transaction, Consultant will not engage in any of
        the
        following activities: (a) participate in the negotiation of terms and conditions
        of the sale and purchase of any securities of Client; (b) assist Client in
        the
        distribution of materials relating to the sale of any securities of Client;
        (c)
        prepare any analysis or provide any advice to any potential investors regarding
        the benefits or potential return relating to the purchase of any securities
        of
        Client; (d) directly assist Client or any prospective investor of securities
        of
        Client with the completion of a Transaction; (e) facilitate the sale, exchange
        or transfer of securities of Client or any handling of any funds received
        from
        the potential investors for any securities of Client, (f)
        discuss
        the details of a proposed Transaction with a potential investor, and (g)
        make
        recommendations to a potential investor with respect to a Transaction.

       

      
        
           

        

        
           

          
            

          

        

        
           

        

      

       

      Client
        understands and agrees that Consultant may retain a broker/dealer to assist
        Consultant in certain aspects of a Transaction. In addition, Client understands
        and agrees that if Client requests Consultant to undertake services causing
        Consultant to become or to be deemed a “broker-dealer”, then investors might
        have a right of rescission or an action for damages with respect to Transactions
        in which the Consultant is deemed to be a broker-dealer.

       

      2.  Term;
        Termination.
        

       

      2.1.  Term.
        The
        term of this Agreement shall commence on the date hereof and shall continue
        until the twelve month anniversary of the date set forth above (the
“Initial
        Term”).
        This
        Agreement will automatically renew for unlimited consecutive additional three
        (3) month periods unless either party provides written notice of non-renewal
        to
        the other party at least thirty (30) days prior to the expiration of the
        Initial
        Term or any renewal period thereafter as the case may be (the Initial Term
        and
        such renewal period, if any, shall be referred to herein as the “Term”).
        

       

      2.2.  Termination.
        Upon
        termination of this Agreement, except as otherwise provided herein, Client’s
        sole responsibility to Consultant shall be to pay Consultant for any unpaid
        fees
        or other consideration earned pursuant to this Agreement.

       

      3.  Compensation;
        Reimbursement. 

       

      3.1.  Signing
        Fee.
        Within
        ten (10) business days of executing this Agreement, Client shall issue to
        Consultant 1.0 million shares of its common stock. The Consultant shall have
        the
        right to allocate this ownership stake as it finds necessary in the course
        of
        providing services for Client. 

       

      3.2.  Additional
        Payments.
        To the
        extent that the Consultant successfully assists in the closing of a Transaction,
        an additional payment, either in cash or in additional shares of common stock
        or
        common stock warrants, will become due to the Consultant (the “Milestone
        Payment”). It is understood that the Client and Consultant will create a
        separate arrangement to this Agreement, mutually agreed upon in good faith,
        to
        govern the size and form of the Milestone Payment.

       

      3.3.  Registration
        of Securities.
        If, at
        any time or from time to time, Client shall determine to register any of
        its
        equity securities, either for its own account or the account of a stockholder,
        Client shall promptly (but in no event less than thirty (30) days prior to
        registration) give Consultant written notice thereof; and shall include in
        such
        registration (and any related qualifications including compliance with Blue
        Sky
        laws), and in any underwriting involved therein, all shares of common stock
        held
        by Consultant, as specified in a written response(s) by Consultant, made
        within
        20 days after receipt of the written notice of registration from Client.
        Notwithstanding any other provision of this Section 3.5, if the registration
        by
        Client is for a registered public offering involving an underwriting and
        the
        managing underwriter determines that marketing factors require a limitation
        of
        the number of shares to be underwritten, the percentage of shares of securities
        to be registered for sale by Client and Consultant shall be equally reduced.
        If
        the registration by Client is for a registered public offering involving
        an
        underwriting, Consultant agrees that it shall (i) not effect any public sale
        or
        distribution (including sales pursuant to Rule 144) of equity securities
        of
        Client or any securities convertible into or exchangeable or exercisable
        for
        such securities and (ii) provide upon request, customary lock-up agreements
        for
        itself and its affiliates by which they agree not to sell any of their shares
        of
        common stock for a period of 180 days from the effective date of the
        registration statement, or for such other length of time determined by the
        managing underwriter. In addition to the rights set forth above, Consultant
        shall be entitled to request, at any time and in any number of requests,
        that
        Client file a registration statement on Form S-3 (or any successor form to
        Form
        S-3) for an offering of shares of common stock of Client held by Consultant
        having an aggregate market value (net of underwriters’ discounts and
        commissions) of at least $500,000 and the Client is a registrant entitled
        to use
        Form S-3 to register the shares of common stock for such an offering, Client
        shall use its commercially reasonable efforts to cause such shares of common
        stock to be registered for the offering on such form and to cause such shares
        of
        common stock to be qualified in such jurisdictions as Consultant may reasonably
        request. If such offer is to be an underwritten offering, the underwriter
        shall
        be selected by Consultant.

       

      
        
           

        

        
          2

          
            

          

        

        
           

        

      

       

      3.4.  No
        Reduction Due to Other Advisors.
        No fee
        payable to any other financial advisor either by Client or any other entity
        shall reduce or otherwise affect the compensation, fees, payments or
        reimbursements payable hereunder to Consultant.

       

      4.  Work
        Product.
        Consultant shall promptly and fully disclose to Client in writing all Work
        Products (as defined below), and the entire right, title and interest to
        all
        such Work Products (including, without limitation the entire right, title
        and
        interest to any renewals, reissues, extensions, substitutions, continuations,
        continuations in part, or divisions that may be filed with respect to the
        Work
        Products) shall be Client’s exclusive property and all Work Products developed
        by Consultant are hereby assigned to Client. Consultant will, at Client’s
        expense, give Client all assistance reasonably required to perfect, protect,
        and
        use the Work Products. The obligations of Consultant pursuant to this Section
        4
        shall survive for the one (1) year period immediately following termination
        of
        this Agreement. As used herein, “Work
        Product”
means
        any work product, improvement, discovery, design, work or idea (whether
        patentable or not and including those which may be subject to copyright
        protection, trademark protection or other intellectual property rights
        protection) generated, conceived, created or reduced to practice by Consultant
        alone or in conjunction with others, during or after working hours, that
        relates
        directly or indirectly to Client’s or its subsidiaries’ businesses or to
        Client’s actual research or development.

       

      5.  Representations
        and Warranties of Client.
        Client
        agrees to cooperate with Consultant and will furnish to, or cause to be
        furnished to, Consultant all information and data concerning the Client (the
        “Information”)
        which
        Consultant reasonably deems appropriate in connection with the services to
        the
        Client as provided herein and will provide Consultant with access to the
        Client’s officers, directors, employees and advisors. The Client represents and
        warrants that all Information made available to Consultant by the Client
        with
        respect to any Transaction included or incorporated by reference into a related
        private placement memorandum or prospectus will be complete and correct
in
        all
        material respects as of the date such Information is provided, and as of
        the
        closing date of the related Transaction, and will not be misleading or violate
        the anti-fraud provisions of the Exchange Act in any material respect,
and
        that
        any projections, forecasts or other Information provided by the Client to
        Consultant will have been prepared in good faith and will be based upon
        reasonable assumptions and projections. The Client agrees to promptly notify
        Consultant if the Client believes that any Information which was previously
        provided to Consultant has become materially misleading. The Client acknowledges
        and agrees that in rendering its services hereunder, Consultant will be using
        and relying on the Information (and information available from public sources
        and other sources deemed reliable by Consultant) without independent
        verification thereof or independent appraisal or evaluation of the Client
        or any
        party to a Transaction. Consultant does not assume responsibility for the
        accuracy or completeness of the Information. If all or any portion of the
        business of the Client is engaged in through subsidiaries or other affiliates,
        the references in this paragraph to the Client will, when appropriate, be
        deemed
        also to include all such subsidiaries or other affiliates.

       

      6.  Indemnification.
        Client
        agrees to indemnify and hold harmless the Consultant and its affiliates and
        their respective directors, officers, managers, attorneys, finders, agents,
        representatives, advisors, stockholders, members and employees, and each
        person,
        if any, who controls Consultant within the meaning of the Securities Act
        of
        1933, as amended (the “Securities
        Act”)
        and
        the Exchange Act (collectively, the “Consultant
        Indemnified Parties”)
        in
        accordance with the provisions for indemnification and contribution set forth
        in
Attachment
        “A”
        hereto,
        which is incorporated by reference in and made a part of this Agreement as
        if
        fully set forth herein. 

       

      
        
           

        

        
          3

          
            

          

        

        
           

        

      

       

      7.  Advertisements.
        With the
        prior written consent of Client, which shall not be unreasonably withheld,
        Consultant shall have the right to place advertisements in mailings and
        financial and other newspapers and journals at its own expense describing
        its
        services hereunder to Client relating to any consummated Transaction and
        using
        Client’s logo, slogan, trademark, and/or service mark.

       

      8.  Confidentiality.
        

       

      8.1.  Restrictions
        on Consultant.
        Consultant recognizes that its relationship with Client will give it access
        to
        non-public proprietary information, confidential information and trade secrets.
        Consequently, during the Term of this Agreement and for the two (2) year
        period
        immediately thereafter, Consultant will not use or disclose for itself or
        for
        others (except persons specifically designated by Client) any Confidential
        Information. “Confidential
        Information”
shall
        include but not be limited to, any information concerning Client’s processes,
        products, services, inventions, purchasing, accounting, marketing, selling
        methods and techniques, research and development, computer programs, purchasing
        information, ideas and plans for development, historical financial data and
        forecasts, long range plans and strategies, customer lists, Information and
        any
        other information related to Client’s customers, and any such other information
        concerning the business of Client or its manner of operation which is not
        generally known in the industry. Confidential Information shall not include
        any
        information that: (i) is or subsequently becomes publicly available without
        Consultant’s breach of this Agreement; (ii) was in the Consultant’s possession
        at the time of disclosure and was not acquired from Client; (iii) is received
        from third parties, and is rightfully in the possession of such third parties
        and not subject to a confidentiality obligation of third parties; (iv) is
        required by law to be disclosed (with prior notice to Client); or (v) is
        intentionally disclosed without restriction by Client to a third
        party.

       

      8.2.  Restrictions
        on Client.
        Client
        agrees that any advice or communication, written or oral, provided by Consultant
        pursuant to this Agreement will be treated by Client as confidential, will
        be
        solely for the information and assistance of Client in connection with its
        consideration of a Transaction and will not be used, circulated, quoted or
        otherwise referred to for any other purpose, nor will it be filed with, included
        in or referred to, in whole or in part, in any registration statement, proxy
        statement or any other communication, whether written or oral, prepared,
        issued
        or transmitted by Client or any affiliate, director, officer, employee, agent
        or
        representative of any thereof, without, in each instance, Consultant’s prior
        written consent. Client further agrees that it will not disclose the identity
        of
        Consultant, the existence of this Agreement or the engagement created hereby
        or
        Consultant’s role with respect to any Transaction without the prior written
        consent of Consultant, other than as may be required by applicable law or
        regulations, including any requirements imposed under the Securities Act
        or the
        Exchange Act; provided,
        that in
        the event such disclosure is required under applicable law or regulation,
        Client
        shall notify Consultant and provide Consultant with an opportunity to review
        and
        provide comments with respect to such proposed disclosure not less than two
        (2)
        business days prior to making such disclosure; provided,
        further,
        that if
        Consultant fails to respond to Client within two (2) business days of receipt
        of
        such proposed disclosure, Consultant shall be deemed to have consented to
        such
        proposed disclosure and waived its right to review and provided comments
        with
        respect to such disclosure. 

       

      8.3.  Third
        Party Information.
        Client
        recognizes that Consultant has received, and in the future may receive, from
        third parties their confidential or proprietary information subject to a
        duty on
        the Consultant’s part to maintain the confidentiality of such information and to
        use it only for certain limited purposes. Consultant agrees at all times
        during
        the Term of this Agreement, not to commingle the Confidential Information
        with
        other third parties’ confidential or proprietary information.

       

      
        
           

        

        
          4

          
            

          

        

        
           

        

      

       

      9.  Surrender
        of Material upon Termination of Agreement.
        Upon
        termination of this Agreement, Consultant shall return immediately to Client
        all
        Work Products including, but not limited to, books, records, notes, data
        and
        information relating to Client or its business, and will so certify in writing
        that it has done so.

       

      10.  Conflicts.
        Client
        acknowledges that Consultant and its affiliates have and will continue to
        have
        other relationships with parties other than Client pursuant to which Consultant
        may acquire information of interest to Client. Consultant shall have no
        obligation to disclose such information to Client, or to use such information
        in
        connection with any contemplated Transaction. Client recognizes that Consultant
        is being engaged hereunder to provide the consulting services described above
        only to Client and is not acting as an agent or a fiduciary of, and shall
        have
        no duties or liability to, the equity holders of Client or any third party
        in
        connection with its engagement hereunder, all of which are hereby expressly
        waived. No one other than Client (and such other parties in such capacities,
        if
        any) is authorized to rely upon the engagement of Consultant hereunder or
        any
        statements, advice, opinions or conduct by Consultant.

       

      11.  Miscellaneous.

       

      11.1.  Notices. Any
        notices desired, required or permitted to be given hereunder shall be delivered
        personally or mailed, certified or registered mail, return receipt requested,
        or
        delivered by overnight courier service, to the following addresses, or such
        other addresses as shall be given by notice delivered hereunder, and shall
        be
        deemed to have been given upon delivery, if delivered personally, three (3)
        business days after mailing, if mailed, or one (1) business day after timely
        delivery to the overnight courier service, if delivered by overnight courier
        service:

       

      If
        to
        Consultant: 

      

      Calico
        Capital Management, LLC

      767
        3rd
        Avenue,
        38th
        Floor

      New
        York,
        NY 10017

      Facsimile:
        (646) 514.4385

      Attn:
        Michael L. Clofine

      

      With
        a
        copy to 

      

      Reed
        Smith LLP

      599
        Lexington Avenue, 29th
        Floor

      New
        York,
        NY 10022

      Facsimile:
        (212) 521.5450

      Attn:
        Herbert F. Kozlov, Esq.

      

      If
        to
        Client: 

      

      WinWin
        Gaming, Inc.

      8687
        West
        Sahara Avenue

      Suite
        201

      Las
        Vegas, NV 89117

      Facsimile:
        (702) 212.4553

      Attn:
        Pat
        Rogers

       

      
        
           

        

        
          5

          
            

          

        

        
           

        

      

      

      or
        to
        such other address as such party may indicate by a written notice delivered
        to
        the other party hereto.

       

      11.2.  Attorneys’
        Fees.
        If any
        party to this Agreement brings an action or proceeding directly or indirectly
        based upon this Agreement or the matters contemplated hereby against another
        party, the prevailing party shall be entitled to recover, in addition to
        any
        other appropriate amounts, its reasonable costs and expenses in connection
        with
        such action or proceeding, including, but not limited to, reasonable attorneys’
fees and court costs.

       

      11.3.  Governing
        Law; Jurisdiction.
        It is
        the intention of the parties that this Agreement shall be subject to and
        shall
        be governed by and construed in accordance with the internal laws of the
        State
        of New York without reference to its choice of law provisions. All actions
        and
        proceedings arising out of or
        relating
        to this Agreement
        shall
        be
        heard and determined exclusively in any New
        York
state
        or
        federal
        court sitting in New
        York,
        New
        York
        (Borough of Manhattan).
        The
        parties hereto hereby (a) submit
        to
        the exclusive jurisdiction of any such court for the purpose of any claim,
        action, suit, proceeding, arbitration, mediation or
        investigation
        (an
        “Action”)
        arising out of or
        relating
        to this Agreement
        brought
        by any party hereto, and (b) irrevocably
        waive, and agree not to assert by way of motion, defense, or
        otherwise,
        in any such Action,
        any
claim
        that
        it
        is not subject personally to the jurisdiction of the above-named courts,
        that
        its property is exempt or
        immune
        from attachment or
        execution,
        that the Action
        is
        brought in an inconvenient forum, that the venue of the Action
        is
        improper, or
        that
        this
Agreement
        or
        the
        transactions contemplated hereby may not
        be enforced in or
        by
        any of
        the above-named courts.

       

      11.4.  Entire
        Agreement.
        This
        Agreement sets forth the entire understanding of the parties relating to
        the
        subject matter hereof, and supersedes and cancels any prior communications,
        understandings and agreements between the parties with respect to the subject
        matter contemplated herein. 

       

      11.5.  Amendment;
        Waiver.
        This
        Agreement may not be amended or modified except by a writing executed by
        both of
        the parties hereto. The waiver by any party hereto of any breach of any
        provision hereunder
        shall
        not
        operate or
        be
        construed as a waiver of any prior or
        subsequent
        breach of the same or
        any
        other
        provision hereunder.

       

      11.6.  Assignability.
        Neither
        party to this Agreement may assign its rights and obligations under this
        Agreement without the prior written consent of the other party.

       

      11.7.  Binding
        Effect.
        This
        Agreement and any amendment thereto, shall be binding upon and shall inure
        to
        the benefit of the successors and assignees of the parties hereto.

       

      11.8.  Relationship.
        Nothing
        in this Agreement shall be interpreted to provide that Consultant and Client
        are
        partners, joint venturers, agents or assignees of the other. Consultant is
        and
        shall remain an independent contractor providing services to Client, and
        is not
        an employee or agent of Client, and neither party shall be entitled to bind
        the
        other party in any way.

       

      11.9.  Headings.
        The
        section headings herein are intended for reference and shall not by themselves
        determine the construction or interpretation of this Agreement.

       

      11.10.  Severability.
        Should a
        court or other body of competent jurisdiction determine that any provision
        in
        this Agreement is invalid or unenforceable, the remaining provisions in this
        Agreement nevertheless shall be deemed valid and enforceable, and continue
        in
        full force and effect without being impaired or invalidated in any
        way.

       

      
        
           

        

        
          6

          
            

          

        

        
           

        

      

       

      11.11.  Further
        Assurances.
        The
        parties shall execute, acknowledge and deliver any further documents,
        instruments, or other assurances and shall take any other action consistent
        with
        the terms of this Agreement that may be reasonably requested by any other
        party
        or its counsel for the purpose of confirming or effectuating any of the actions
        contemplated by this Agreement.

       

      11.12.  Remedies
        Cumulative.
        Any
        termination of this Agreement shall be without prejudice to any right or
        remedy
        to which a party may be entitled either by law, or in equity, or under this
        Agreement.

       

      11.13.  Survival.
        Notwithstanding
        any termination of this Agreement, Sections 2.2, 3, 4, 6, 8, 9 and this Section
        11 shall survive and remain in full force and effect.

       

      11.14.  Counterparts.
        This
        Agreement may be executed in one or more counterparts, all of which taken
        together shall constitute one and the same Agreement.

       

      

      

      

      

      [Signature
        Page Follows]

       

      
        
           

        

        
          7

          
            

          

        

        
           

        

      

      

      

      IN
        WITNESS WHEREOF, the parties hereto have executed this Agreement on the date
        first set forth above.

       

      
        	 	
                Consultant

                 

                CALICO
                  CAPITAL MANAGEMENT, LLC

                 

                /s/
                  Michael L.
                  Clofine                                    
                  

                By: Michael
                  L. Clofine

                Its: Chief
                  Executive Officer and President

                 

                 

              
	 	 
	 	
                Client

                 

                WINWIN
                  GAMING, INC.

                 

                /s/
                  Patrick
                  Rogers                                          
                  

                By: Patrick
                  Rogers

                Its:
                  Chief Executive Officer and President

              
	 	 

      

      

      

       

      

      
        
           

        

        
           

          
            

          

        

        
           

        

      

       

      Attachment
        “A”

       

      Indemnification
        and Contribution

       

      The
        Client shall indemnify and hold harmless Consultant and each of its controlling
        persons, subsidiaries, affiliates, directors, officers, and employees
        (“Indemnified
        Persons”),
        from
        and against all losses, claims, damages and liabilities, and all suits, actions,
        claims, proceedings and investigations in respect thereof, relating to or
        arising out of the activities contemplated by Consultant’s engagement described
        in the Consulting Agreement to which this Attachment “A” is attached. The
        foregoing shall include the reasonable expenses incurred by Consultant and
        Indemnified Persons in appearing as witnesses or being deposed, producing
        documents or otherwise being involved in any suits, actions, proceedings
        or
        investigations. The Client shall
        reimburse Consultant and each Indemnified Person for all reasonable expenses,
        including attorneys' fees and disbursements, as they are incurred in connection
        with investigating, preparing for or defending any suit, action, proceeding
        or
        investigation, whether or not Consultant or such Indemnified Person shall
        be a
        party thereto, whether or not the same shall involve or result in any liability
        on the part of Consultant or such Indemnified Person; provided that the Client
        shall advance such expenses only upon receipt of an undertaking by Consultant
        or
        such person to repay such advances if it shall ultimately be determined that
        Consultant or such person was not entitled to be indemnified.
        Notwithstanding the forgoing, the
        Client
        shall
        not, however, be obligated to indemnify Consultant or any Indemnified Person
        in
        respect of any loss, claim, damage, liability or expense to the extent the
        same
        is found by a final judgment of a court of competent jurisdiction to have
        resulted from gross negligence, willful misconduct or bad faith on the part
        of
        Consultant or such Indemnified Person.
        Consultant shall have no liability to the Client for any loss, claim, damage,
        liability or expense related to or arising out of the activities contemplated
        by
        Consultant’s engagement, except to the extent such loss, claim, damage,
        liability or expense is found by a final judgment of a court of competent
        jurisdiction to have resulted from gross negligence, willful misconduct or
        bad
        faith on the part of Consultant.

       

      If
        any
        suit, action, claim, proceeding or investigation is instituted against
        Consultant or any Indemnified Person aforesaid in respect of which
        indemnification may be sought hereunder, Consultant or such person shall
        promptly notify the Client thereof in writing, but the omission so to notify
        the
        Client shall not relieve the Client from any liability except to the extent
        the
        Client shall have been materially prejudiced by such omission. Neither
        Consultant nor any Indemnified Person shall be required to provide notice
        to the
        Client with respect to any suit, action or proceeding in which the Client
        is
        named a defendant. The
        Client shall be entitled to assume the defense of any suit, action or proceeding
        with counsel reasonably satisfactory to Consultant; provided,
        however,
        that if
        the defendants in any such suit, action or proceeding include both Consultant
        or
        an Indemnified Person and the Client or another indemnified person, and counsel
        for Consultant or such Indemnified Person shall have advised in writing that
        a
        conflict or potential conflict exists between Consultant or such Indemnified
        Person and the Client or another indemnified person, or that there may be
        one or
        more legal defenses available to Consultant or an Indemnified Person which
        are
        different from or additional to those available to the Client or another
        indemnified person, then the Client shall not have the right to assume the
        defense of such suit, action or proceeding on behalf of Consultant or such
        Indemnified Person, and Consultant and such Indemnified Person shall have
        the
        right to select separate counsel to defend such suit, action or proceeding
        on
        its behalf, with costs to be borne by Client. Subject to the foregoing, the
        Client shall not be liable for the expenses of more than one separate counsel
        (in addition to local counsel) for Consultant and all Indemnified Persons
        similarly situated in any one suit, action or proceeding or substantially
        similar suits, actions or proceedings in the same jurisdiction arising out
        of
        the same general allegations or circumstances.
        The
        Client shall not be liable for the settlement of any suit, action, claim
        or
        proceeding by Consultant or any Indemnified Person without the Client’s prior
        written consent. The Client agrees that it shall not settle any suit, action,
        claim or proceeding relating to or arising out of the activities contemplated
        by
Consultant’s
        engagement,
        unless such settlement includes a provision unconditionally releasing Consultant
        and each Indemnified Person from all liabilities in respect of the matters
        which
        are the subject of such suit, action claim or proceeding. The provisions
        hereof
        are in addition to all other existing rights to indemnification on the part
        of
        Consultant and each Indemnified Person aforesaid, and shall survive any
        termination of Consultant’s
        engagement hereunder.

       

      
        
           

        

        
          1

          
            

          

        

        
           

        

      

       

      In
        order
        to provide for just and equitable contribution, if a claim for indemnification
        hereunder is made, but it is found in a final judgment of a court of competent
        jurisdiction that such indemnification may not be enforced in such case,
        even
        though the express provisions hereof provide for indemnification in such
        case,
        then the Client, on the one hand, and Consultant, on the other hand, shall
        contribute to the amounts paid, payable or suffered in respect of the losses,
        claims, damages, liabilities or expenses for which indemnification is
        unavailable or insufficient (i) in such proportion as appropriately reflects
        the
        relative benefits to the Client, on the one hand, and Consultant, on the
        other
        hand, from the transaction contemplated by Consultant’s engagement hereunder, or
        (ii) if the allocation provided by clause (i) is not permitted by applicable
        law, in such proportion as appropriately reflects not only the relative benefits
        referred to in clause (i), but also the relative faults of the Client, on
        the
        one hand, and Consultant, on the other hand, in connection with the statements,
        acts or omissions which resulted in such losses, claims, damages, liabilities
        or
        expenses, as well as any other relevant equitable considerations. It is agreed
        that it would not be just or equitable if the contribution provided for herein
        were determined by pro rata allocation or any other method which does not
        take
        into account the foregoing. The relative benefits to the Client and Consultant
        shall be deemed to be in the proportion which (A) the total amount to be
        paid by
        the Client from the transaction contemplated by Consultant’s engagement (whether
        or not consummated), bears to (B) the fees actually received by Consultant
        for
        its engagement (excluding any amounts received in reimbursement of expenses).
        In
        no event shall Consultant’s share of any liability be in excess of the fees
        actually received by Consultant for its engagement (excluding any amounts
        received in reimbursement of expenses).

       

       

       

       

       

       

      
        
           

        

        
          2Unassociated Document

    AMENDED
      AND RESTATED LICENSE AGREEMENT

     

    This
      Amended and Restated License Agreement (the “Agreement”) is entered into and
      made effective as of this 6th
      day of
      September 2006, (the “Effective Date”) by and between CORNERSTONE BIOPHARMA,
      INC., a Nevada corporation (“Cornerstone”), and AURIGA
      LABORATORIES,
      INC., a Delaware corporation (“Auriga”) collectively the “Parties.”

     

    BACKGROUND

     

    
      	 	
              1.

            	
              WHEREAS,
                Fleming and Company Pharmaceuticals (“Fleming”) is the owner of all right,
                title and interest in and to certain trademark rights and other rights
                in
                technology relating to the pharmaceutical product EXTENDRYLTM (as further
                defined below, the “Products”);

            

    

     

    
      	 	
              2.

            	
              WHEREAS,
                Fleming and Champion Pharmaceutical, Inc. (“Champion”) previously
                entered into a License Agreement, dated August 27, 2004 (the
                “Champion-Fleming Agreement”), whereby Champion obtained certain rights
                and licenses from Fleming relating to the above-mentioned trademark
                and
                other rights;

            

    

     

    
      	 	
              3.

            	
              WHEREAS,
                Pursuant to the terms of the Champion-Fleming Agreement, Champion
                sublicensed its rights in the Champion-Fleming Agreement to Tryon
                in a
                License Agreement dated October 1, 2004 (the “Champion-Tryon Agreement”),
                whereby Fleming was entitled to the same consideration from Tryon
                as it
                was entitled to under the Champion-Fleming
                Agreement;

            

    

     

    
      	 	
              4.

            	
              WHEREAS,
                Pursuant to a December 15, 2004 agreement, Fleming sublicensed its
                rights
                in the above-mentioned trademark and other rights directly to Tryon
                (the
                “Tryon-Fleming Agreement”), in consideration for which Tryon will pay a
                fee to Champion, thereby terminating the Champion- Fleming
                Agreemen;

            

    

     

    
      	 	
              5.

            	
              WHEREAS,
                Pursuant to a January 1, 2005 agreement, Tryon sublicensed its rights
                in
                the above-mentioned trademark and other rights to an affiliate of
                Cornerstone in exchange for a royalty payable to Tryon, Champion
                and
                Fleming;

            

    

     

    
      	 	
              6.

            	
              WHEREAS,
                Tryon, Auriga, and Champion entered into a reorganization transaction
                on
                April 15, 2005;

            

    

     

    
      	 	
              7.

            	
              WHEREAS,
                Pursuant to a May 24, 2005 agreement (as amended), Cornerstone’s affiliate
                exclusively sublicensed its rights in the above-mentioned trademark
                and
                other rights to Auriga in exchange for a royalty payable to such
                Cornerstone affiliate;

            

    

     

    
      	 	
              8.

            	
              WHEREAS,
                by letter dated March 23, 2006, Auriga, Cornerstone and Cornerstone’s
                affiliate confirmed their intent that Cornerstone, rather that
                Cornerstone’s affiliate, be party to the relevant agreements;
                and

            

    

     

    
      	 	
              9.

            	
              WHEREAS,
                Auriga and Cornerstone wish to amend the terms of their
                relationship.

            

    

     

    Now,
      in
      consideration of the above, Cornerstone and Auriga desire to memorialize the
      terms of their arrangement.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    TERMS
      AND CONDITIONS

     

    NOW
      THEREFORE, in consideration of the foregoing and of the mutual covenants and
      agreements hereinafter set forth, the Parties agree as follows:

     

    
      	1	
              Definitions.
                For purposes of this Agreement, the following terms will have the
                following meanings:

            

    

     

    1.1    “Affiliates”
      means any corporation, partnership, or other entity controlling, by, or under
      common control with (directly or indirectly) a party to this :; “control”
(including, with correlative meaning, the terms “control,” “controlled by” and
“under common control with”) means the possession, directly or indirectly, of
      the power to direct or cause the direction of management, whether through the
      ownership of voting securities or by contract or otherwise.

     

    1.2    [omitted].

     

    1.3    “FDA”
      means the United States Food and Drug Administration.

     

    1.4    “Licensed
      Rights” means trademark rights in EXTENDRYLTM and any proprietary information
      relating to formulations, the testing of formulations, sales and marketing
      information, historical financial data and regulatory information that relate
      directly to Fleming’s products sold under the Extendryl mark.

     

    1.5    “Products”
      means any product marketed and sold under the ExtendrylTM mark or that is
      substantially similar in formulation to any of the ExtendrylTM products sold by
      Auriga, Fleming or Cornerstone, including any product line extensions or generic
      versions.

     

    1.6    “Net
      Sales” means with respect to any Products, the gross amount invoiced by Auriga
      (or its Affiliates or sublicensees) for the Products sold, less (i) quantity
      and/or cash discounts from the gross invoice price which are actually taken;
      (ii) freight, postage and insurance included in the invoice price;
      (iii) amounts repaid or credited by reasons of rejections or return of
      goods, (iv) third-party rebates and chargebacks actually repaid or
      credited, and (v) invoiced customer duties and sales taxes (excluding income,
      value-added and similar taxes), if any, actually paid.

     

    1.7    “NDA”
      means a
      new drug application (whether original, supplementary or abbreviated) to the
      applicable regulatory authority, for approval by such regulatory authority,
      necessary for the commercial sale of product. An NDA, together with all
      supplemental filings referencing the initial NDA filing, shall be deemed one
      and
      the same NDA for all purposes of this Agreement..

     

    
      	
              2

            	
              License
                Grant

            

    

     

    Effective
      as of August 1, 2005 (the “Effective Date of the License”), Auriga will be
      granted an exclusive, world-wide, perpetual license, including the right to
      grant sublicenses, subject to section 4 below, to use the Licensed Rights,
      and
      the goodwill associated therewith, in connection with the sale, marketing,
      and
      promotion of Products, subject to the terms and conditions contained herein.
      Auriga shall use diligent commercial efforts to sell Products. 

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        	3	
                Consideration

              

      

    

     

    3.1    Closing
      Payment.
      Within
      five (5) business days of the Effective Date, Auriga shall issue and deliver
      to
      Cornerstone 200,000 shares of Auriga’s common stock (the “Closing Payment”).

     

    3.2    Royalty.
      In
      consideration of the licenses granted herein, Auriga shall pay to Cornerstone
      a
      percentage of Net Sales as a royalty (“Royalty”) in accordance with the
      following:

     

    
      	
              Period

            	
              Royalty

                Percentage

            
	
              Net
                Sales in Q3, 2006

            	
              30%

            
	
              Net
                Sales in Q4, 2006

            	
              10%

            
	
              Net
                Sales in Q1, 2007

            	
              10%

            
	
              Net
                Sales in Q2, 3, 4, 2007

            	
              8%

            
	
              Net
                Sales in 2008

            	
              7%

            
	
              Net
                Sales in 2009 and thereafter

            	
              5%

            

    

    

    No
      later
      than thirty (30) days from the end of each calendar quarter during the term
      of
      this Agreement, Auriga shall provide to Cornerstone a written report setting
      forth the Net Sales of Products during the previous quarter together with
      payment of all amounts shown to be due in such report. In the event of a good
      faith dispute, undisputed amounts shall be paid in accordance with this Section
      3.2 and the parties shall work in good faith to resolve any such dispute,
      following which any additional amounts, if any, shall be paid promptly.
      Royalties payable for the period July 1, 2006 through September 30, 2006 shall
      be payable only on sales of products that bore a royalty under the May 24,
      2005
      agreement (as amended) referenced in the recitals above. 

     

    3.3    Assumption
      of Royalty Responsibility.
      Auriga,
      on behalf of itself and its Affiliates, will pay directly to Fleming, any
      royalties due Fleming under the Tryon-Fleming Agreement on behalf of any party
      for sales occurring after October 1, 2005.

     

    3.4    Payment
      from Tryon to Champion.
      After
      July 1, 2005, Champion’s right to receive royalties will terminate.

     

    
      	
              4

            	
              Sublicenses.
                Auriga shall have the right to sublicense the Licensed Rights subject
                to
                the terms of this Agreement.

            

    

     

    
      	
              5

            	
              Generic
                Substitutes.
                Each party hereto agrees that it will not manufacture, cause to
                manufacture, sell or cause to be sold generic versions of the other
                party’s products. The obligation of a party not to manufacture, cause to
                manufacture, sell or cause to be sold generic versions of the other
                party’s products shall apply only to the products that are marketed by
                the
                other party immediately prior to the first to occur of (a) an assignment
                of this Agreement by either party or (b) a merger, share exchange
                or other
                transaction that results in a change in beneficial ownership of at
                least
                50% of the voting shares of either party.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              6

            	
              Cornerstone
                Obligations.

            

    

     

    6.1    Cornerstone
      may, at any time, submit a new drug application (“NDA”) for a product or
      products containing the active ingredient methscopolamine. Cornerstone shall
      bear all responsibility, and all costs, associated with such NDA and obtaining
      and maintaining FDA approval for such product. Auriga agrees that it shall
      not,
      during the term of this Agreement, submit an NDA for a product or products
      containing the active ingredient methscopolamine and Auriga shall cause any
      sublicensees of rights related to Product not to file such an application.
      

     

    6.2    Upon
      request of Auriga, Cornerstone will provide Auriga with information relating
      to
      ExtendrylTM product formulation, manufacture, and testing, customer lists,
      physician lists, and supplier lists, provided, however, that Cornerstone makes
      no representations or warranties with respect to the accuracy or completeness
      of
      such information or its fitness for any particular purpose, and provided further
      that Cornerstone shall have no obligations to manufacture any ExtendrylTM
products after the Effective Date of the License.

     

     

    7     Right
      of Manufacture. Cornerstone
      agrees that, in the event it obtains approval from the FDA under Section
      505(b)(2) of the Food, Drug and Cosmetic Act (“FD&C Act”) to manufacture or
      sell a product containing the active ingredient methscopolamine, Auriga shall
      automatically be granted a license to manufacture and sell any of Extendryl
      HC,
      Extendryl PSE, Extendryl DM, Extendryl Seniors, Extendryl Juniors, Extendryl
      Chewables and Extendryl Syrup, in each case, as formulated with methscopolamine
      on the date of this Agreement, in accordance with the approval granted under
      Section 505(b)(2) of the FD&C Act and all applicable laws. The foregoing
      licenses shall bear a royalty as provided in Section 3.2 and shall be
      irrevocable, except that Cornerstone may revoke the license if (a) Auriga
      engages in conduct that materially jeopardizes the continuing validity of the
      approval and fails promptly to cure any such violation or (b) Auriga fails
      to
      pay required royalties. The foregoing license is expressly limited to rights
      under the applicable approval and shall not constitute an express or implied
      license to any patent, trademark or other intellectual property right of the
      licensor.

     

    8            
      Warranties
      and Representations of Cornerstone.
      Cornerstone warrants and represents as follows: 

     

    8.1    Cornerstone
      has all right, title and interest in and to the Licensed Rights, necessary
      and
      sufficient to grant the rights contemplated by this Agreement, such ownership,
      right, title and interest, free and clear of all encumbrances, liens and rights
      of third parties.

     

    8.2    To
      the
      best of Cornerstone’s knowledge, there is no third party using or infringing the
      Licensed Rights;

     

    8.3    Cornerstone
      has not granted, conveyed, licensed or assigned any rights in the Licensed
      Rights to any third party.

     

    8.4    To
      the
      best of Cornerstone’s knowledge there are no legal, governmental or regulatory
      proceedings pending against or otherwise involving Cornerstone relating to
      any
      Licensed Rights.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              9

            	
              Confidential
                Information

            

    

     

    9.1    Nondisclosure.
      The
      parties agree to maintain the confidentiality of confidential information
      provided under this Agreement pursuant to the terms of the Confidential
      Information Non-Disclosure Agreement executed between the parties (the
“CINDA”).

     

    9.2    Survival.
      The
      confidentiality provisions of this Section 9 and the CINDA will survive the
      termination of this Agreement and remain in full force and effect for a period
      of 5 years thereafter.

     

    
      	
              10

            	
              Term
                and Termination

            

    

     

    10.1    Term.
      This
      Agreement shall extend indefinitely and until terminated for any of the
      following reasons:

     

    10.1.1  Termination
      for Material Breach.
      Either
      party may terminate this Agreement upon a material breach of this Agreement
      by
      the other party; provided however, that the terminating party must first give
      the other party written notice, which notice must state the nature of the breach
      in reasonable detail and that the terminating party views such alleged Material
      Breach as a basis for terminating this Agreement under this Section and such
      other party must have failed to cure that alleged breach within 30 days after
      receipt of such notice. 

     

    10.1.2  Termination
      for Insolvency.
      This
      Agreement may be terminated by either party, with termination effective
      immediately upon written notice to the opposite party if the opposite party
      makes an assignment for the benefit of its creditors, files a voluntary petition
      under federal or state bankruptcy or insolvency laws, a receiver or custodian
      is
      appointed for that party’s business, or proceedings are instituted against that
      party under federal or state bankruptcy or insolvency laws that have not been
      stayed or dismissed within sixty (60) days. All rights and licenses granted
      under or pursuant to this Agreement are, and shall otherwise be deemed to be,
      for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights
      to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy
      Code.

     

    10.1.3  Effect
      of Termination.
      In the
      event that either party exercises the termination provisions of Section 10.1,
      the license granted to Auriga under Section 2 of this Agreement shall be
      terminated and rights will revert to those set forth in the January 1, 2005
      agreement referenced in the recitals above, provided that Cornerstone, rather
      than its affiliate, shall be the sublicensee of Tryon. 

     

    
      	
              11

            	
              Indemnifications
                and Insurance

            

    

     

    11.1   Indemnification
      of Cornerstone.
      Auriga
      and/or its Affiliates shall indemnify and hold Cornerstone and its officers,
      directors, shareholders, agents and employees harmless against any and all
      liability, damage, loss, cost or expense, including reasonable attorneys’ fees,
      resulting from any third party claim made or suit brought against Auriga or
      such
      persons to the extent such claim is caused by or arises out of (i) Auriga’s or
      its Affiliates negligence or willful misconduct, (ii) Auriga’s material breach
      of any terms of this Agreement, or (iii) the manufacturing, marketing,
      distribution, sale or use of the Products by Auriga or any third party,
      including any Product manufactured by Cornerstone but sold by Auriga or its
      Affiliate after the Effective Date of the License. Upon the filing of any such
      claim or suit, Cornerstone shall immediately notify Auriga thereof and shall
      permit Auriga at its cost to handle and control such claim or suit. Cornerstone
      shall have the right to participate in the defense of such claim or suit at
      its
      own expense. Notwithstanding anything else in this paragraph, Auriga shall
      have
      no indemnification obligation to the extent any claim arises out of the gross
      negligence or willful misconduct of Cornerstone.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    11.2   Indemnification
      of Auriga.
      Cornerstone shall indemnify and hold Auriga and its officers, directors,
      shareholders, agents and employees harmless against any and all liability,
      damage, loss, cost or expense, including reasonable attorneys’ fees, resulting
      from any third party claim made or suit brought against Auriga or such persons
      to the extent such claim is caused by or arises out of (i) Cornerstone’s
      negligence or willful misconduct, (ii) Cornerstone’s material breach of any
      terms of this Agreement, or (iii) Cornerstone’s manufacturing, marketing,
      distribution, sale or use of any Extendryl product(s), except for products
      manufactured by Auriga and sold by Auriga or its Affiliate after the Effective
      Date of the License. Upon the filing of any such claim or suit, Auriga shall
      immediately notify Cornerstone thereof and shall permit Cornerstone at its
      cost
      to handle and control such claim or suit. Auriga shall have the right to
      participate in the defense of such claim or suit at its own expense.
      Notwithstanding anything else in this paragraph, Cornerstone shall have no
      indemnification obligation to the extent any claim arises out of the gross
      negligence or willful misconduct of Auriga.

     

    11.3   Insurance.
      Auriga
      shall maintain general commercial liability, including products liability,
      insurance with a limit of no less than 5 million dollars in the aggregate.
      During the term of this Agreement, Cornerstone shall be named as an additional
      insured on Auriga’s policy for any and all claims arising from the Products or
      this Agreement. A certificate of insurance, a copy of which shall be forwarded
      to Cornerstone, shall evidence such insurance. The policy will not be cancelled
      or altered so as to reduce coverage unless and until Cornerstone shall have
      received thirty (30) days written notice.

     

    
      	
              12

            	
              General

            

    

     

    12.1           
      Relationship
      of the Parties.
      The
      parties agree that each is acting as an independent contractor with respect
      to
      the other and nothing contained in this Agreement is intended, or is to be
      construed, to constitute a partnership or joint venture or agency relationship.
      Neither party hereto shall have any express or implied right or authority to
      assume or create any obligations on behalf of or in the name of the other party
      or to bind the other party to any contract, agreement or
      undertaking.

     

    12.2            Notices.
      Any
      notice or other communication hereunder shall be in writing and shall be deemed
      given when so delivered in person, by overnight courier (with receipt
      confirmed), by facsimile transmission (with receipt confirmed by telephone
      or by
      automatic transmission report) or upon receipt if sent by certified mail, return
      receipt requested, as follows (or to such other persons and/or addresses as
      may
      be specified in writing to the other party hereto):

     

    
      	If to AURIGA 	 	Auriga Laboratories, Inc. 
              5555
                Triangle Parkway, Suite 300 

              Norcross,
                GA 30092

              Attn:
                Philip S. Pesin 

              Fax
                (678) 282-1700 

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	If to CORNERSTONE: 	 	Cornerstone BioPharma, Ltd. 
              2000
                Regency Parkway, Suite 255 

              Cary,
                NC 27511 

              Attn:
                Craig Collard 

              Fax:
                (919) 678-6599

            

    

     

    12.3    Successors
      and Assigns.
      The
      term and provisions of this Agreement are assignable by and shall inure to
      the
      benefit of, and be binding upon each party and their respective successors,
      assigns, heirs and personal representatives.

     

    12.4    Amendment.
      No
      amendment or modification of this Agreement will be binding unless it is in
      a
      writing, which states that it is an amendment to this Agreement, and is signed
      by both parties to this Agreement.

     

    12.5    Governing
      Law.
      This
      Agreement shall be governed by and construed in accordance with the laws of
      the
      State of Delaware, without regard to the choice of law principles of any
      jurisdiction.

     

    12.6    Waiver
      of Breach.
      The
      waiver or failure of either party to enforce the terms of this Agreement in
      one
      instance will not constitute a waiver of that party’s rights under this
      Agreement with respect to other violations. No waiver of any of the terms of
      this Agreement will be binding unless it is in writing and signed by the party
      granting the waiver.

     

    12.7    Severability.
      If any
      provision hereof should be held invalid, illegal or unenforceable in any respect
      in any jurisdiction, then, to the fullest extent permitted by law, all other
      provisions hereof shall remain in full force and effect in such jurisdiction
      and
      shall be liberally construed in order to carry out the intentions of the parties
      hereto as nearly as may be possible; provided, however, that nothing herein
      shall be construed so as to defeat the overall intention of the
      parties.

     

    12.8    Survival.
      The
      provisions of Sections 3, 7, 8, 9, 11, and 12, and any other provision which
      by
      its terms is intended to survive the termination of this Agreement will survive
      the termination of this Agreement and remain in full force and effect
      thereafter.

     

    12.9    Execution
      in Counterparts.
      This
      Agreement may be executed in any number of counterparts, each of which
      counterparts, when so executed and delivered, shall be deemed to be an original,
      and all of which counterparts, taken together, shall constitute one and the
      same
      instrument.

     

    12.10        
      Entire
      Agreement and Cancellation of Previous Agreements.
      This
      Agreement, together with all documents referred to herein (including the CINDA)
      and all exhibits and schedules attached hereto or thereto, contains the entire
      agreement and understanding of the parties, and supersedes any prior agreements
      or understandings between the parties with respect to the subject matter of
      this
      Agreement.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    12.11   Remedies.
      The
      parties agree, that in addition to any other relief afforded under the terms
      of
      this Agreement or by law, each party has the right to enforce this Agreement
      by
      injunction issued against the other party, it being understood that both damages
      and an injunction will be proper modes of relief and are not to be considered
      as
      alternative remedies.

     

    

     

    IN
      WITNESS WHEREOF, the parties have executed this Agreement as of
      the
      date
      first above written.

     

     

    
      	CORNERSTONE BIOPHARMA,
              INC.	 	
              AURIGA
                LABORATORIES, INC. 

            
	 	 	 	 
	By:
              	/s/
              CRAIG COLLARD	 	/s/
              PHILIP S. PESIN
	 	
              CRAIG COLLARD  

              PRESIDENT AND CEO

            	 	PHILIP S. PESIN
              
              CHAIRMAN AND CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]